Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery system.1 Phase 1 results show a manageable ...

BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, ... (TAR-210). Additionally, the Phase 3 MoonRISe-1 (BLC3004, NCT06319820) ...

About TAR-210 TAR-210 is an investigational intravesical erdafitinib releasing system. The safety and efficacy of TAR-210 is being evaluated in a Phase 1 study ( NCT05316155 ) in patients with ...

Additionally, Johnson & Johnson will share progress updates on TAR-210, an erdafitinib-releasing system, and other ongoing Phase 3 trials evaluating TAR-200 against traditional therapies.

Erdafitinib is only recommended if the company provides it according to the commercial arrangement. Why the committee made this recommendation Usual treatment for unresectable or metastatic urothelial ...

Erdafitinib is a once-a-day tablet which can be taken at home. NICE based its recommendation on data from a study which showed the medicine to increase overall survival from 7.8 months to 12.1 ...

TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2) Skip to main content. You have permission to edit this article ...

Erdafitinib (Balversa) is available on the NHS. It is a possible treatment for urothelial cancer in adults when the cancer: is unresectable (cannot be surgically removed) or metastatic (has spread to ...